Technical Trend Overview and Price Movement
As of 17 Mar 2026, Anuh Pharma’s share price closed at ₹75.50, down 2.09% from the previous close of ₹77.11. The stock’s intraday range was between ₹75.50 and ₹86.40, indicating some volatility but an inability to sustain higher levels. The 52-week high stands at ₹115.00, while the 52-week low is ₹68.00, placing the current price closer to the lower end of its annual range.
The technical trend has deteriorated from mildly bearish to outright bearish, signalling a shift in market sentiment. This is corroborated by the daily moving averages which remain bearish, suggesting that short-term price momentum is negative. The bearish stance is further reinforced by Bollinger Bands on both weekly and monthly charts, which are also bearish, indicating that price volatility is skewed towards the downside.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On a weekly basis, the MACD remains mildly bullish, hinting at some underlying positive momentum in the short term. However, the monthly MACD is bearish, reflecting longer-term weakness. This divergence between weekly and monthly MACD readings suggests that while there may be short-lived rallies, the broader trend remains negative.
The Know Sure Thing (KST) indicator aligns with this view, showing mild bullishness on the weekly chart but bearishness on the monthly timeframe. This oscillation between short-term optimism and longer-term caution is typical of stocks undergoing consolidation or distribution phases before a decisive move.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
RSI and Volume-Based Indicators
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This lack of momentum confirmation from RSI suggests that the stock is neither oversold nor overbought, which may imply a period of consolidation or indecision among investors.
On-Balance Volume (OBV) also fails to indicate a definitive trend, with no clear directional movement on weekly or monthly timeframes. This absence of volume confirmation weakens the conviction behind any price moves, signalling that trading activity is not strongly supporting either bulls or bears at present.
Dow Theory and Moving Averages
According to Dow Theory, the weekly trend is mildly bearish, while the monthly trend is mildly bullish. This contrast again highlights the tension between short-term weakness and longer-term resilience. However, the daily moving averages remain bearish, reinforcing the near-term negative outlook.
Investors should note that the micro-cap status of Anuh Pharma adds an additional layer of risk and volatility, often resulting in sharper price swings and less liquidity compared to larger peers in the Pharmaceuticals & Biotechnology sector.
Comparative Returns and Market Context
When analysing returns relative to the Sensex, Anuh Pharma has underperformed over most recent periods. The stock declined 3.01% over the past week compared to a 2.66% drop in the Sensex. Over one month, the stock fell 6.81%, while the Sensex dropped 9.34%, showing a slightly better relative performance in the short term.
Year-to-date, Anuh Pharma is down 6.19%, outperforming the Sensex’s 11.40% decline. However, over the one-year horizon, the stock has declined 1.47% while the Sensex gained 2.27%, indicating a lagging performance. Over longer periods, the stock has delivered strong absolute returns, with 88.02% over three years and 47.97% over five years, though these lag the Sensex’s 31.00% and 49.91% respectively. The ten-year return of 38.28% pales in comparison to the Sensex’s 205.90%, underscoring the stock’s micro-cap volatility and sector-specific challenges.
Mojo Score and Analyst Ratings
Anuh Pharma’s current Mojo Score stands at 34.0, categorised as a Sell rating. This represents a downgrade from a previous Strong Sell grade as of 4 Feb 2026, reflecting a slight improvement but still signalling caution. The downgrade aligns with the technical deterioration and the bearish signals from multiple indicators.
The micro-cap classification and the pharmaceutical sector’s inherent regulatory and competitive risks contribute to the cautious stance. Investors should weigh these factors carefully against the stock’s recent price momentum and technical outlook.
Considering Anuh Pharma Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Investor Takeaway and Outlook
In summary, Anuh Pharma Ltd is currently navigating a challenging technical landscape. The shift from mildly bearish to bearish trend, supported by bearish daily moving averages and monthly MACD, suggests that downside risks remain elevated. The lack of strong volume confirmation and neutral RSI readings imply that the stock may continue to consolidate or face further pressure before any sustained recovery.
Long-term investors should consider the stock’s historical returns and sector fundamentals, but remain cautious given the micro-cap volatility and recent technical deterioration. Short-term traders may find opportunities in the mild weekly bullish signals from MACD and KST, but these are counterbalanced by the broader bearish context.
Overall, the technical indicators and market performance suggest that Anuh Pharma Ltd remains a speculative investment with a Sell bias, requiring close monitoring of momentum shifts and volume trends for any signs of reversal.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
